Prof. Arlene Sharpe
George Fabyan Professor of Comparative Pathology, Head of the Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston MA, USA
Visit co-ordinated by Michelle Wykes email@example.com
18 August Seminar and meetings at ANU, Canberra (host: Ian Cockburn)
19 August Seminar and meetings in Sydney (host: Mainthan Palendira)
29-30 August Seminar and meetings at QIMR Berghofer (host: Michelle Wykes)
Arlene Sharpe MD, PhD, is a member of the Department of Pathology at Brigham and Women’s Hospital and Leader of the Cancer Immunology Program at the Dana-Farber/Harvard Cancer Center. Dr. Sharpe is the Co-Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital.
Dr. Sharpe earned her A.B from Harvard University and her M.D. and Ph.D. degrees from Harvard Medical School. She completed residency training in Pathology at Brigham and Women’s Hospital and is board certified in Anatomic Pathology. Dr. Sharpe has served as a member and chair of the NIH Hypersensitivity, Autoimmunity and Immune-mediated diseases (HAI) study section and is currently a member of NIAID Council. She is also the Vice President of the American Association of Immunologists.
Dr. Sharpe is a leader in the field of T cell costimulation, and investigates how costimulatory pathways regulate immune responses. Her laboratory has discovered and elucidated the functions of T cell costimulatory pathways, including the immunoinhibitory functions of the CTLA-4 and PD-1 pathways, which have become exceptionally promising targets for cancer immunotherapy. Her laboratory currently focuses on the roles of T cell costimulatory pathways in regulating T cell tolerance and effective antimicrobial and antitumor immunity. Her laboratory also is involved in studies aimed at translating fundamental understanding of T cell costimulation into new therapies for autoimmune diseases and cancer. Dr. Sharpe has published over 300 papers and was listed by Thomas Reuters as one of the most Highly Cited Researchers (top 1%) in 2014 and 2015. She received the William B. Coley Award for Distinguished Research in Tumor immunology in 2014 for her contributions to the discovery of PD-1 pathway.